More Phase III data back upcoming dolutegravir filings in HIV
This article was originally published in Scrip
Executive Summary
The Phase III data required for initial regulatory filings of the investigational integrase inhibitor dolutegravir in adults infected with HIV "are in house", according to the joint venture Shionogi-ViiV Healthcare.